OLEMA PHARMACEUTICALS INC (OLMA)
Health Care · Clinical-stage oncology / breast cancer therapeutics · NASDAQ
Olema is a clinical-stage biopharmaceutical company advancing palazestrant, a dual estrogen receptor antagonist and degrader, for hormone-positive breast cancer.
What OLEMA PHARMACEUTICALS INC does
Olema is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation targeted therapies for breast cancer and beyond. The company's lead candidate, palazestrant, is a small-molecule oral drug with dual activity as a complete estrogen receptor (ER) antagonist and selective ER degrader currently in late-stage clinical trials for ER+/HER2− metastatic breast cancer both as monotherapy and in combination with targeted agents. Olema is also developing OP-3136, a KAT6 inhibitor, and leverages its expertise in endocrine-driven cancers and mechanisms of acquired resistance.
Themes: ["Breast cancer / ER+ metastatic breast cancer","Estrogen receptor antagonists / endocrine therapy","Targeted oncology","Nuclear receptor modulation","Acquired resistance mechanisms","Epigenetic modulation / KAT6 inhibition"]
Fundamentals
- Price$12.28 as of 2026-07-09 close
- Market cap$1.1B as of 2026-07-10
- 1-year return+165.0% as of 2026-07-09 close
- ROE-46.0% as of 2026-07-10
- Debt / equity0.01 as of 2026-07-10
- Beta1.99 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial failure: OPERA-01 and OPERA-02 Phase 3 trials may not meet efficacy or safety endpoints, delaying or preventing FDA approval and commercial launch of palazestrant in 2027–2029.","Regulatory and development timelines: Achievement of FDA approval and commercialization depends on successful NDA submission and regulatory review; delays or unfavorable decisions could significantly impact the company's path to profitability.","Competition from established therapies: The company faces competition from major pharmaceutical firms already offering CDK4/6 inhibitors and other ER+/HER2− breast cancer treatments, which may limit market penetration and pricing power for palazestrant."]
Competitors & peers
- Eli Lilly (LLY)
- Roche/Genentech
- Novartis (NVS)
- AstraZeneca (AZN)
- Pfizer (PFE)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.